Aura Biosciences Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

AURA$7.65-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Deficit	Loss Amount	Equity
Balance, December 31, 2023	49,350,788	—	512,617	(287,308)	539	225,848
Stock-based compensation expense	—	—	2,909	—	—	2,909
Employee stock purchase plan	12,314	—	95	—	—	95
Stock option exercises	51,180	—	158	—	—	158
Vesting of restricted stock	90,123	—	—	—	—	—
Unrealized gain on marketable securities	—	—	—	—	(521)	(521)
Net loss	—	—	—	(19,706)	—	(19,706)
Balance, March 31, 2024	49,504,405	—	515,779	(307,014)	18	208,783
Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Deficit	Loss Amount	Equity
Balance, December 31, 2022	37,771,918	—	406,555	(210,900)	(72)	195,583
Stock-based compensation expense	—	—	1,913	—	—	1,913
Stock option exercises	21,549	—	145	—	—	145
Employee stock purchase plan	6,635	—	56	—	—	56
Unrealized loss on marketable securities	—	—	—	—	27	27
Net loss	—	—	—	(17,466)	—	(17,466)
Balance, March 31, 2023	37,800,102	—	408,669	(228,366)	(45)	180,258

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.